Cargando…
Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
The aim of the study was to investigate the therapeutic value of reinduction therapy with the same cytostatic treatment that had been used for induction treatment in patients with metastatic colorectal cancer. A total of 71 patients, all of whom had responded or achieved stable disease lasting >...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062977/ https://www.ncbi.nlm.nih.gov/pubmed/9743296 |
_version_ | 1782137241875775488 |
---|---|
author | Hejna, M. Kornek, G. V. Raderer, M. Depisch, D. Brodowicz, T. Fiebiger, W. C. Scheithauer, W. |
author_facet | Hejna, M. Kornek, G. V. Raderer, M. Depisch, D. Brodowicz, T. Fiebiger, W. C. Scheithauer, W. |
author_sort | Hejna, M. |
collection | PubMed |
description | The aim of the study was to investigate the therapeutic value of reinduction therapy with the same cytostatic treatment that had been used for induction treatment in patients with metastatic colorectal cancer. A total of 71 patients, all of whom had responded or achieved stable disease lasting > or = 12 weeks after six monthly courses of first-line treatment with 5-fluorouracil + racemic leucovorin (5-FU/LV; n = 35) or 5-FU plus the l-isomer of LV (LLV; n = 34) were entered in this study. At the time of relapse, the same treatment was used for initial therapy: racemic LV or LLV was administered at 100 mg m(-2) day(-1) by i.v. bolus injection, immediately followed by 5-FU 400 mg m(-2) day(-1) given as a 2-h infusion. Chemotherapeutic drugs were given on 5 consecutive days at 4-week intervals x 6 or until there was evidence of tumour progression. Among 49 evaluable patients, reinduction therapy that was initiated after a median treatment-free interval of 5.4 months (range 3-14.5) resulted in nine partial response (PR) (18%) and 26 stable disease (SD) (53%), yielding an overall tumour control rate of 69% (95% confidence interval, 54.6-81.7%). The median time to treatment failure from reinduction was 6.4 months, and the median survival duration from reinduction was 8.9 months (20.1 months as judged from the beginning of induction therapy). The toxicity associated with retreatment was generally mild to moderate; compared with initial treatment, there was no significant difference in terms of the overall rate (P = 0.33) or severity (P = 0.19) of adverse reactions. Our data suggest that in patients with advanced colorectal cancer an interrupted treatment strategy, i.e. retreatment with the same regimen in case of relapse > or = 3 months after discontinuation of 6 months of successful treatment with 5-FU/LV or 5-FU/LLV is an acceptable therapeutic concept. |
format | Text |
id | pubmed-2062977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1998 |
publisher | Nature Publishing Group|1 |
record_format | MEDLINE/PubMed |
spelling | pubmed-20629772009-09-10 Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Hejna, M. Kornek, G. V. Raderer, M. Depisch, D. Brodowicz, T. Fiebiger, W. C. Scheithauer, W. Br J Cancer Research Article The aim of the study was to investigate the therapeutic value of reinduction therapy with the same cytostatic treatment that had been used for induction treatment in patients with metastatic colorectal cancer. A total of 71 patients, all of whom had responded or achieved stable disease lasting > or = 12 weeks after six monthly courses of first-line treatment with 5-fluorouracil + racemic leucovorin (5-FU/LV; n = 35) or 5-FU plus the l-isomer of LV (LLV; n = 34) were entered in this study. At the time of relapse, the same treatment was used for initial therapy: racemic LV or LLV was administered at 100 mg m(-2) day(-1) by i.v. bolus injection, immediately followed by 5-FU 400 mg m(-2) day(-1) given as a 2-h infusion. Chemotherapeutic drugs were given on 5 consecutive days at 4-week intervals x 6 or until there was evidence of tumour progression. Among 49 evaluable patients, reinduction therapy that was initiated after a median treatment-free interval of 5.4 months (range 3-14.5) resulted in nine partial response (PR) (18%) and 26 stable disease (SD) (53%), yielding an overall tumour control rate of 69% (95% confidence interval, 54.6-81.7%). The median time to treatment failure from reinduction was 6.4 months, and the median survival duration from reinduction was 8.9 months (20.1 months as judged from the beginning of induction therapy). The toxicity associated with retreatment was generally mild to moderate; compared with initial treatment, there was no significant difference in terms of the overall rate (P = 0.33) or severity (P = 0.19) of adverse reactions. Our data suggest that in patients with advanced colorectal cancer an interrupted treatment strategy, i.e. retreatment with the same regimen in case of relapse > or = 3 months after discontinuation of 6 months of successful treatment with 5-FU/LV or 5-FU/LLV is an acceptable therapeutic concept. Nature Publishing Group|1 1998-09 /pmc/articles/PMC2062977/ /pubmed/9743296 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Hejna, M. Kornek, G. V. Raderer, M. Depisch, D. Brodowicz, T. Fiebiger, W. C. Scheithauer, W. Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. |
title | Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. |
title_full | Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. |
title_fullStr | Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. |
title_full_unstemmed | Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. |
title_short | Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. |
title_sort | reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062977/ https://www.ncbi.nlm.nih.gov/pubmed/9743296 |
work_keys_str_mv | AT hejnam reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer AT kornekgv reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer AT radererm reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer AT depischd reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer AT brodowiczt reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer AT fiebigerwc reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer AT scheithauerw reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer |